Researchers at Genzyme have found a way to deliver drugs that shut down the genes associated with the neuromuscular disease myotonic dystrophy type 1, a type of muscular dystrophy.
A Sanofi plant that benefited from problems at its Genzyme subsidiary in the past is benefiting from Sanofi's good fortune now.
Genzyme, the biotech subsidiary of Sanofi, is experimenting with continuous processing, a new manufacturing approach that potentially can shave time, space and equipment costs by eliminating the batch approach to production.
Sanofi's ($SNY) Genzyme unit has set the price on its new rare-disease drug Kynamro: $176,000. That's steep, but it's part and parcel the super-niche-market strategy that's Big Pharma's new bread and butter.
The FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY) Genzyme unit.
Manufacturing biotech drugs inside living cells is a complex and expensive task. But two big outfits, Amgen and Sanofi's Genzyme, are racing to develop a new process that promises to significantly reduce the cost of proteins and antibodies, according to a story in MIT's Technology Review.
Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval.
Amicus Therapeutics revealed its success in a small midstage study of its drug to enhance enzyme therapy in patients with the rare genetic disorder Pompe disease. On the back of the upbeat data, the biotech company's shares recovered some of the lost ground from news last month of a Phase III failure for its lead candidate.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
A European Medicines Agency panel handed down a negative opinion late this week on the antisense drug from Isis Pharmaceuticals for treating a genetic disease that causes blood cholesterol to jump, citing safety concerns such as signs of liver toxicity and cardiovascular risks in patients in clinical trials.